JPX PRIME

3649

Supplementary Information on Q3FY2026 Quarterly Business Results Summary

FINDEX Inc.

November 12, 2026

FINDEX

©2026 FINDEX Inc.

Cautionary Statement

This material is provided for informational purposes only and does not constitute a solicitation of any action based on this material.

This document (including the business plan) has been prepared by the Company based on reliable information available at the time of preparation, but it contains risks and uncertainties, and the Company assumes no responsibility for its accuracy or completeness.

Furthermore, even where it is desirable to update or revise forecasts or plans, the Company is under no obligation to update or revise the information in this material.

The Company assumes no responsibility whatsoever for any losses that may arise from investment decisions based on the forecasts and target figures contained in this document.

The copyright of this material belongs to FINDEX Inc.

No part of this material may be reproduced or distributed in any form or by any means without the prior written permission of the Company.

In the graphs and tables of this document, some of the figures are rounded up or truncated for the purpose of adjusting fractional values.

©2026 FINDEX Inc.

INDEX

01 / FINDEX Inc. Corporate Information

02 / Q3FY2026 Financial Highlights

03 / Q3FY2026 Segment Performance

04 / Appendix

©2026 FINDEX Inc.

01 / FINDEX Inc. Corporate Information
02 / Q3FY2026 Financial Highlights
03 / Q3FY2026 Segment Performance
04 / Appendix

01

FINDEX Inc.
Corporate Information

FINDEX is a team of experts dedicated to supporting medical and public institutions through our solutions, driven by continuous innovation and growth.



Medical Business

- Used by approximately 80% of university hospitals in Japan
- Solving healthcare challenges through technology



Public Sector Business

- Developing essential e-approval and public document management solutions for public sector DX
- Rapid growth in adoption at prefectural governments and government-affiliated organizations

FINDEX

Enriching Society
Through the Creation of
Valuable Technology

Health Tech Business




- Medical devices with proprietary technologies, deployed in Japan and overseas
- Driving the government-led utilization of medical data

©2026 FINDEX Inc.

Historical Performance and Plan for 2030

Expanding EPS through stable growth and new growth segments, while ensuring continuous shareholder returns



Fiscal Year	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27P	FY28P	FY29P	FY30P
EPS (¥)	17.1	19.4	14.2	15.5	19.5	16.8	24.8	28.2	41.3	45.3	50.2	53.3	66.1	77.5	86.7	96.3
Payout Ratio (%)	41.1	36.1	49.2	48.4	41.0	47.6	34.2	33.7	31.5	33.1	43.9	50.0	50.0	50.0	50.0	50.0
Annual Dividend per share (¥)	7.00	7.00	7.00	7.50	8.00	8.00	8.50	9.50	13.00	15.00	22.00	27.00	33.00	39.00	43.00	48.00

*EPS is calculated based on net income

Plan

©2026 FINDEX Inc.

01 / FINDEX Inc. Corporate Information
02 / Q3FY2026 Financial Highlights
03 / Q3FY2026 Segment Performance
04 / Appendix

02

Q3FY2026
Financial Highlights

Q1-3FY2026 KEY TAKEAWAYS

Net sales

¥4,297 mio

YoY: -1.7 %

Progress Rate: 69.2 %

Overall progress on track

Operating profit

¥985 mio

YoY: -17.5 %

Progress Rate: 53.9 %

Costs up due to upfront investment

Operating margin of 22.9%

FY2026 Forecast

Net sales **¥6,209 mio**

Operating profit **¥1,829 mio**

Earnings forecast: Unchanged

- Net sales and profit are seasonally concentrated in Q1 and Q4. The Q1-3 progress rate against the full-year forecast is as planned (net sales are in line with the five-year average at the end of Q3)
- Net sales and operating profit are expected to increase in Q4, led by the strong Medical Business
- Continuing upfront investments for mid- to long-term growth, including strengthening specialist personnel and in-house system infrastructure

©2026 FINDEX Inc.

Q1-3FY2026 Financial Highlights

- Medical Business performed well against the full-year forecast, covering the Public Sector sales decline and Health Tech delays


(¥Million)	Q1-3FY2026	YoY (Changes)	Initial Forecast (FY2026)	Achievement Rate	Remarks
Net sales	**4,297**	-1.7%	6,209	69.2%	Net sales are concentrated in Q1 and Q4 each year. Q4 is steadily progressing.
Medical Business	**3,967**	-1.2%	5,451	72.8%	Held up well despite the gap between system renewal cycles (full-year forecast YoY -4.2%)
Public Sector Business	**265**	-10.0%	419	63.5%	YoY trend improving from H1
Health Tech Business	**64**	4.5%	340	19.0%	*GAP* sales below plan and delayed launch of Medical Data PF
Gross profit	**2,755**	-2.0%	-	-	
SG&A	**1,769**	9.4%	-	-	Expenses increased due to personnel costs and firm-wide infrastructure/Cyber security enhancement
Operating profit	**985**	-17.5%	1,829	53.9%	Full-year forecast expected to be achieved, led by the Medical Business
Medical Business	**1,106**	-9.2%	-	-	
Public Sector Business	**42**	-62.9%	-	-	
Health Tech Business	**-162**	-	-	-	
Ordinary profit	**1,034**	-16.6%	1,889	54.8%	
Profit attributable to owners of parent	**639**	-25.1%	1,302	49.1%	Impact of approx. ¥100M impairment loss on investment securities

Medical Data PF: Medical Data Platform Business


©2026 FINDEX Inc.

Q1-3FY2026 Factors Contributing to Changes in Operating Profit

Factors Affecting Operating Profit Changes (¥Million)



Factors Affecting Segment Profit Changes (¥Million)



Increase in expenses for investments in business expansion and for improving operational efficiency and productivity

- Continued base salary increases + hiring of new frontline staff
- Renewal of internal ERP system
- Active investment in cybersecurity measures

©2026 FINDEX Inc.

Q1-3FY2026 Consolidated Balance Sheet

B/S (¥Million)	FY2025	Q1-3FY2026	Changes
CURRENT ASSETS	3,744	**3,325**	-419
Cash and deposits	1,679	**1,616**	-63
Accounts receivable - trade and contract assets	1,787	**1,404**	-383
Merchandise and finished goods, work in progress	171	**175**	4
Raw materials and supplies	20	**17**	-3
Other	86	**111**	25
NON-CURRENT ASSETS	3,064	**3,017**	-47
Property, plant and equipment	86	**95**	9
Intangible assets	300	**288**	-12
of which: Software	299	**287**	-12
Investments and other assets	2,679	**2,633**	-46
of which: Investment securities	2,218	**2,061**	-157
TOTAL ASSETS	6,807	**6,343**	-464
LIABILITIES	1,341	**920**	-421
TOTAL CURRENT LIABILITIES	1,027	**608**	-419
TOTAL NON-CURRENT LIABILITIES	314	**311**	-3
Long- and short-term interest-bearing liabilities	0	**0**	0
NET ASSETS	5,467	**5,423**	-44
TOTAL LIABILITIES and NET ASSETS	6,807	**6,343**	-464

©2026 FINDEX Inc.

Quarterly Net Sales, Orders and Backlog Trends



* Orders and backlog exclude recurring revenue from maintenance services and SaaS fees
* Net sales include maintenance service and SaaS fees

©2026 FINDEX Inc.

01 / FINDEX Inc. Corporate Information
02 / Q3FY2026 Financial Highlights
03 / Q3FY2026 Segment Performance
04 / Appendix

03

Q3FY2026
Segment Performance

FY2026 Net Sales Forecast and Business Strategies by Segment

FY2026 Full-Year Forecast

Net sales: **¥6,209 mio** YoY **+1.6%**
Operating profit: **¥1,829 mio** YoY **+2.2%**


		Business Strategies by Segment	Initiatives to Achieve the Forecast
Medical Business	**Net Sales Forecast** **¥5,451 mio** YoY **-4.2%** Q3 progress rate: 72.8%	• **Large hospitals: gradual rollout of cloud services** • **Clinics: promoting cloud-based services** • **Continuing stable operation of HPKI Second Electronic Certificates for e-prescriptions and handling new applications** • **Focusing on new project mandate funded by the supplementary budget for medical institutions** (partially recorded this fiscal year)	• Focusing on cloud services unaffected by hardware procurement difficulties • Actively capturing replacement demand for ophthalmic clinic EMRs • Number of facilities using electronic prescriptions grew by approx. 2,500 YoY
Public Sector Business	**Net Sales Forecast** **¥419 mio** YoY **+17.9%** Q3 progress rate: 63.5%	• **Establishing efficient sales channels and enhancing functionality** • **Strengthening HR and organizational capabilities in line with business expansion**	• Won multiple contract bids from small and medium-sized municipalities • Hired sales talents • Acquiring new distributors and strengthening existing distributors
Health Tech Business	**Net Sales Forecast** **¥340 mio** YoY **+437.2%** Q3 progress rate: 19.0%	• **Advancing various projects in the Medical Data Platform Business to facilitate the utilization of electronic medical record data** • **Executing the rebaselined domestic medical device sales plan and accelerating overseas sales**	• Preparation of the new data business facility (operation center) in Tokyo is largely complete • Expanded overseas sales coverage for GAP; new lot shipment completed in Q4

©2026 FINDEX Inc.


Medical Business (1/3)

- Although this year falls between system renewal cycles, stronger cross-selling and the addition of new services have significantly narrowed the decline in revenue and profit. Progress against the full-year forecast is also on track. Operating margin was 27.9% (30.3% in previous year)
- Orders using the supplementary budget (subsidies) also increased, and the order backlog is building steadily.
  Revenue is scheduled to be recognized from next fiscal year onward

Net Sales (¥Million)



Operating Profit (¥Million)




©2026 FINDEX Inc.

Medical Business (2/3)


- Recurring revenue from maintenance and cloud services in the Medical segment **rose to 35.9% of the total** (vs. 33.2% YoY)
- Use of cloud-based products such as *CocktailAI* and *PiCIs Connect* continues to expand. Services related to the EHR Information Sharing Service, which facilitates medical data interoperability, as well as those supporting hospital-to-hospital and hospital-to-clinic collaboration, are expected to be key growth drivers going forward

Sales Composition Ratio by Products & Services (%)


Previous year: As of Q1-3FY2025



Current year: As of Q1-3FY2026



Sales Composition Ratio by Size of Users (%)



©2026 FINDEX Inc.


Medical Business (3/3) Market Environment

Market Environment

- Investment appetite among medical institutions is rising, driven by the FY2026 Medical Fee Revision*1 and the cabinet's approval of the supplementary budget. This positive market environment encouraging the adoption of IT solutions acts as a strong tailwind for medical system vendors
- The government has accelerated its EMR adoption targets, aiming for 100% adoption among hospitals with 200 or more beds by FY2028 and approximately 100% across all medical institutions by the end of 2030. At the same time, it is promoting support for security measures and stronger standards to protect medical data
- The government supports the development and adoption of cloud-native products compatible with the EHR Information Sharing Service. Infrastructure is being built with an eye toward future “secondary use” through the aggregation and database creation of medical data

*1: The medical fee schedule sets official prices for healthcare services paid to medical institutions and is revised biennially in principle (drug prices annually) by the government

Growth Forecast on Japanese Medical, Healthcare and Pharma DX Market




Calculated based on Fuji Keizai's "2025 Current Status and Future Outlook for Medical, Healthcare, and Pharmaceutical DX Markets" and various corporate reports

©2026 FINDEX Inc.


Public Sector Business (1/2)

- Revenue declined temporarily owing to the lapse of major prior-year contracts. Profit declined due to upfront spending on staffing expansion, security measures and AI service investment aimed at strengthening mid- to long-term competitiveness
- Net sales progress against the full-year forecast is 63.5%. Net sales in Q2-Q3 exceeded the prior year, and the YoY decline in revenue and profit narrowed


Net Sales and Operating Profit (¥Million)



Amount of Revenue from Monthly Usage Fee (¥Million)



DocuMaker Office Total Number of Users



* FY22 figures for the Public Sector segment have been retrospectively restated and remain unaudited

©2026 FINDEX Inc.

Public Sector Business (2/2) Market Environment

Market Environment

- Rising demand for official document management systems in the public sector to comply with legal regulations, address staff shortages, improve operational efficiency, and mitigate operation continuity risks
- Adoption of DX products boosted by lower barriers to entry, driven by cloud utilization and enhanced subsidy/grant programs

TAM: Domestic Market Size of Document Management System: approx. ¥74 billion

# of private-sector companies with 10 or more employees: approx. 440,000

SAM: approx. ¥40 billion

# of private-sector companies with 100 or more employees: approx. 50,700
# of Public interest corporations: approx. 9,700

SOM： approx. ¥5.5 billion

# of Municipalities: 40
# of Incorporated Administrative Agencies : 87
# of Local Incorporated Administrative Agencies: 165
# of Public Interest Corporations: approx. 100

Product and services mainly installed in:

Municipality | Incorporated Administrative Agency | Local Incorporated Administrative Agency | Public Interest Corporation | National University Corporation | Admin of hospitals

67 facilities
Public sector

15 facilities
Admn of hospitals


Excerption from Installation History	# of Users
Ehime Prefectural Government	Approx. 5,000
Okayama Prefectural Government	Approx. 6,000
National Research and Development Agency K	Approx. 4,500
Nasu-Shiobara city	Approx. 800
City M	Approx. 4,000
RIKEN National Research and Development Agency	Approx. 2,000

©2026 FINDEX Inc.

Health Tech Business (1/3)

- In the Medical Data Platform Business, the operations go-live date for the utilization of electronic medical record data under the Next Generation Medical Infrastructure Act has been rescheduled to early next fiscal year due to the longer than expected preparatory work.
- Overseas shipment of 50 *GAP* units was completed in October. In addition, shipments to Thailand have started, and sales expansion in the ASEAN region has begun

Net Sales and Operating Profit (¥Million)



Medical Data Platform Business

Existing business based on direct commissions from medical institutions

- Multiple data processing projects in progress, driving the majority of this period's net sales

New business under the Next Generation Medical Infrastructure Act

- Operational readiness and environment setup for the operation center, a facility for secured data utilization. Start of certified business operations is rescheduled to **early next fiscal year**
- Upfront investments, including preparation to go-live the operation center and strengthening the AI analytics team

Medical Device Business

***GAP* (Perimeter)**
Launched in April 2021

- Overseas new lot shipment completed in October
- Focusing on marketing efforts on health checkup centers

MCI diagnostic device
Under development

- Preparations underway for medical device regulatory approval

©2026 FINDEX Inc.

Health Tech Business (2/3) Updates on Medical Device and its Market Trends

Market Environment of Perimeter

- The visual-field testing market is shifting away from de facto standard models, with an increasing number of compact perimeters entering the market
- *GAP* utilizes a patented measurement method based on eye-tracking technology; therefore, the impact of intensifying competition remains limited

Global Market Size of Perimeter: approx. ¥50 billion

Hospitals: approx. ¥9.4bn Clinics: approx.¥19.7bn Others: approx. ¥2.2bn


Domestic Market Size of Perimeter: approx. ¥2.1 billion

Hospitals(incl. check up facilities): approx. ¥0.5bn
Clinics: approx.¥1.6bn

Approx. **2,300**[*1] **Eye hospitals**

Approx. **8,200**[*1] **Eye clinics**

[International] Shipment Share by Region



Product Shipment Milestones



April 2021:
Japan Started domestic sales

August 2023:
Europe, Middle East and Africa Started sales in some regions

January 2025:
Brazil and Taiwan Started sales

From March 2026:
Argentina, Chile and Mexico Preparing for sales

September 2026:
Thailand Started sales

©2026 FINDEX Inc.

Health Tech Business（3/3）Outline of Medical Data Platform Business

Our unrivaled competitive advantage lies in our close, long-standing relationships with hospitals nationwide





FINDEX

- We possess extensive expertise in clinical data management and advanced data control capabilities, cultivated through the development of mission-critical systems for numerous large-scale hospitals
- We have a proven track record in high-quality data extraction, including clinical data labeling and data cleansing

Processed EMR data

Academic Data Analysis & Other Research etc

Sales Model:

- **Project-based (One-time) Revenue:** Revenue recognized per **individual request**
- **Data Services:** Collection and processing of EMR (Electronic Medical Record) data tailored to each project
- **High Profitability:** High-margin model driven by specialized expertise

Drug Development & Improvement

■ Pharma Companies

High demand for “raw” EMR data to analyze post-medication numerical changes, correlations, and efficacy

Reducing Development Lead Times

Diagnostic AI Development

■ AI and Software Developers

High demand for clean, high-quality "training data," which is essential for developing AI-driven medical products.



National Healthcare Advancement as a Catalyst for Our Growth

National Policy

Certified Entity

©2026 FINDEX Inc.

Next Generation Medical Infrastructure Act: List of Certified Entities and Certified Users

Next Generation Medical Infrastructure Act:

The official name is “The Act on Anonymized Medical Information to Contribute to Medical Research and Development”.
This law promotes the use of individual medical data—such as health checkup results and electronic medical records—by allowing such information to be pseudonymized or anonymized for research and development in the medical field. It serves as a special provision under the Act on the Protection of Personal Information, permitting third-party use of medical data without requiring prior consent from individuals.

List of Certified Entities (operators that collect, anonymize and pseudonymize medical information under a secure management framework)

Certified Preparers	General Incorporated Association Life Data Initiative (LDI)	General Incorporated Foundation Japan Medical Association Medical Information Management Organization (J-MIMO)	General Incorporated Foundation Fair and Safe Use of Anonymised Standardised Health Data of Japan (FAST-HDJ)	Certified on: September 30, 2026 Medical AI Promotion Institute Inc. (MAPI)
Enterprises Certified for Entrustment with Handling Medical and Other Information	NTT DATA Japan Corporation	ICI Inc. NS Solutions Corporation	Hitachi, Ltd. **FINDEX Inc.**	

List of Certified Users (operators permitted to use pseudonymously processed medical information)

AstraZeneca K.K.	Tohoku Medical and Pharmaceutical University	Kyushu University
RIKEN	TOPPAN Holdings Inc.	Milliman, Inc.

*Cabinet Office: Certification of business operators under the Next Generation Medical Infrastructure Act (as of the end of October 2026). English names are unofficial translations for reference purposes only.

©2026 FINDEX Inc.

Our Investor Relations Website　Launch of “Discover FINDEX: Business & Industry Guide”

- **FINDEX Inc. IR Website**
  URL:　https://findex.co.jp/en/ir/index.html

- **Discover FINDEX: Business & Industry Guide (Japanese only)**
  URL:　**https://findex-investor-3649.notion.site/info**

  Discover Findex: Business & Industry Guide is a dedicated website where our IR team provides in-depth explanations for our shareholders, investors, and all stakeholders. This covers business details that cannot be fully conveyed in financial reports alone, along with industry trends and responses to FAQs. We encourage all stakeholders to visit for deeper insights into our company.



©2026 FINDEX Inc.

01 / FINDEX Inc. Corporate Information
02 / Q3FY2026 Financial Highlights
03 / Q3FY2026 Segment Performance
04 / Appendix

04

Appendix

Core Stable Segment



1994
Started Medical Business and Software Development

Establishes a solid business foundation in the **Medical DX sector** over more than 30 years

- The Medical Business segment consistently maintains an operating margin of over 30%, generating stable cash flow
- Our medical solutions are used by more than 2,000 hospitals across Japan, including approximately 80% of university hospitals, with a customer retention rate of over 98%

Strategic Growth Segment



2014
Started providing solutions for public sector

2019
Introduced in-house developed medical device both to domestic and global markets

Leverages technical expertise gained in Medical DX to expand into **Public Sector DX** and **medical device development**

- Our Public Sector business continues to expand its track record with local gov’ts and other public-sector organizations, accelerating new project wins.
- The Medical Device business is transitioning from a development-centric phase to an intensive marketing phase
- Together, these segments serve as “side engines”, diversifying our revenue streams beyond the core business



2025
Established Medical Data Platform Business

Participates as a key player in the national strategy for **medical data utilization**, aiming for further transformative growth

- Leverages our advanced, hard-to-replicate technologies, strong industry presence, and relationships with hospitals nationwide to lead the utilization of electronic medical record data
- Develops the Medical Data Platform Business into a new growth driver

©2026 FINDEX Inc.

Dividend/Shareholder Return Policy 2026-2030

Enhancing Shareholder Return
Dividend payout ratio of 50% and a minimum DOE (Dividend on Equity) of 8.5%

Optimization of Capital Efficiency
Optimizing equity capital and maintaining/improving ROE (Return on Equity)


Improvement of TSR
Enhancing IR (Investor Relations) and SR (Shareholder Relations) activities

FY2026 Dividend Forecast

Interim		Year-end		Annual
¥13/Share	+	¥14/Share	=	¥27/Share

※FY2025 Dividend Actual
¥8/Share + ¥14/Share = ¥22/Share


Trends in Dividend and Payout Ratio



©2026 FINDEX Inc.

Net Sales and Operating Profit Trends

- Track Record of Stable Growth: Consistent business expansion driven by our unique market position.
- 10-year CAGR: Revenue 7.6% / Operating Income 10.3%




©2026 FINDEX Inc.


Quarterly Net Sales and Profit Trends

- Our quarterly performance exhibits seasonality, with both sales and profit trending heavily toward the first and fourth quarters (Q1 and Q4). The degree of this concentration fluctuates annually, influenced by the capital expenditure cycles of our primary hospital clients and the specific timing of system go-live dates

Net Sales, Achievement vs. Initial Forecast (¥Million)



Operating Profit, Achievement vs. Initial Forecast (¥Million)



©2026 FINDEX Inc.

Product Implementation Rate and Changes in the Number of Customers (As of September 30, 2026)

Among National, Public and Private University Hospitals in Japan:

Approx. 80%

Installed at **68** out of **81** Medical University Hospitals (Main campus)



Among Large Hospitals in Japan:

Approx. 40%

are our customers

*Reference: Ministry of Health, Labor and Welfare 2023 Survey of Medical Facilities (static and dynamic) and Summary of Hospital Reports


(# of facilities)

Medical Solutions: By Facility Size	Q2FY2026	Q3FY2026	QoQ
Large hospitals (400+ beds)	310	311	+1
Mid-sized hospitals (100-399 beds)	346	347	+1
Small hospitals (20-99 beds)	97	97	0
Clinics (<20 beds), Other	1,516	1,537	+21
Total	**2,269**	**2,292**	**+23**


Public Sector: By Product	Q2FY2026	Q3FY2026	QoQ
Municipal packages	66	67	+1
Ultra large (5,000+ users)	2	2	0
Large (1,000-4,999 users)	3	3	0
Mid-sized (300-999 users)	17	17	0
Small (<300 users)	44	45	+1
Medical facility packages	14	15	+1
Total	**80**	**82**	**+2**

©2026 FINDEX Inc.

Trends in Distributors Sales (¥Million)




Average Numbers of Solutions Installed per Medical Facility



*Due to an increase in new users who introduced SaaS products on a standalone basis

Composition of Sales by Products (%)



* Maintenance service costs/revenue were allocated to each product

©2026 FINDEX Inc.

Trends and Topics in the Medical Software Industry 2026-2030

「Medical DX Reiwa Vision 2030」

Establishment of a National Medical Information Platform

Standardization of EMR Information (Promotion across all medical institutions)

Digitalization of Medical Treatment Fee Amendment

Medical AI・Big Data

- Generally, all medical institutions and pharmacies are connected to the Online Certification System for Healthcare
  →Laying the Groundwork for Data Utilization
- The implementation of the Next Generation Medical Infrastructure Act will expand the collection and utilization of diverse real-world data
- In addition to the Health Insurance Claims Data currently being traded in the market, it will be possible to handle more accurate medical data such as medical records in the future

Advantages for hospitals and healthcare industry:

- Support for diagnosis, treatment, and surgery
- Applications for disease and nursing care prevention and reduction of medical costs
- Development of new markets via data accumulation

Cloud-Based Services

- Cloud-based operations with high security levels are now possible without compromising the "three principles of electronic storage
- In small and medium-sized hospitals and clinics, the use of cloud-based products is expanding, while in large hospitals, on-premises system operation is still common
  →The widespread adoption of cloud storage will likely accelerate as its market prices decrease
- Utilizing the cloud for the development of a Regional Collaboration Network

Advantages for hospitals and healthcare industry:

- Efficient information sharing enables smart coordination with other facilities
- No need for extensive capital investment, server room allocation, or regular system updates

Telemedicine

- The 2022 revision of medical fees has led to an increase in the insurance points for initial consultation fees to 87% of in-person medical care, resulting in a rapid increase in facilities that have introduced telemedicine
- Meanwhile, there is a limited number of medical facilities that offer telemedicine services, and large hospitals are hesitant to fully implement them
  →The applications are limited, primarily in second opinion outpatient settings
- Emergence of teleoperated surgical robots

Advantages for hospitals and healthcare industry:

- Expanding the choice of medical facilities, improving healthcare systems in remote areas and to address medical service disparities
- The reduction of congestion and infection risk due to a drop in patient visits

Electronic Prescriptions

- The Japanese gov't targets all hospitals and pharmacies to implement e-Prescriptions by the end of March 2025, but the extension of transitional measures has been postponed to September 2026 (As of October 2026, the adoption rate is 43.2%)
- Installations during the grace period are eligible for subsidies
- Medical facilities need to install Online Certification System for Healthcare and issue HPKI cards prior to the use of e-Prescriptions

Advantages for hospitals and healthcare industry:

- Optimization of dispensing and counseling tasks
- Prevention of duplicated prescriptions by centralizing management of prescribing information
- Contribution to telemedicine and home care services

Myna Insurance Card

- Following the integration of My Number Cards and health insurance cards, conventional health insurance cards were abolished, with the transition to My Number health insurance cards completed in December 2025
- Smartphone integration is being rolled out sequentially
- Myna Health Insurance Card utilization reached approx. 68.2% (as of April 2026)

Advantages for hospitals and healthcare industry:

- Enhanced healthcare through centralized medical history management
- Reduction of administrative costs

Better Working Environments

- Started in April 2024, overtime work for employed physicians is now limited to no more than 960 hours per year
  →Proper management of working hours is necessary
- The impact on the workstyles of hospital physicians remains limited as of 2026; accelerating DX has become an even more urgent priority from the perspective of operational efficiency

Advantages for hospitals and healthcare industry:

- Improvement in long working hours of physicians
- Sales opportunities for attendance management solutions

Domestic Market Size of Medical Systems: approx. ¥500-600 billion*

*Prepared by the Company based on data including Fuji Keizai's "Domestic Market Survey on Medical Collaboration Systems and Medical Platforms"

©2026 FINDEX Inc.

Enriching Society with Technologies and Creation

Equal Access to Medical Services | **Digitally Connecting Medical Communities** | **Developing New Technologies for Healthy Livings**

FINDEX

- Driving digitalization in and outside medical facilities, offering solutions that revolutionize the business models in the healthcare sector
- Proficient in processing and handling a variety of patient data owned by large hospitals
- Providing consulting as software specialists and applying in-house technology to products for the public sector and medical devices

Domestic

Community-Based Integrated Healthcare

Cloud-based Medical Software

Connecting medical facilities and individuals through cloud-based services

Building a platform for securely managing and exchanging data

Promotion of integrated regional care and collaboration in regional healthcare

Local gov'ts | Elderly care | Home care | Check-up facilities | Patient | Pharmacy

PiCIs

Utilization of collaborative data × Enhancement of functions through AI-generated features

Fitting Cloud — Implementation of cloud-based management analysis &information linkage for medical data / provision of medical AI information technology

Hospital-Centric Healthcare

On-premises Medical Software

Further expansion of flagship product sales

Claio | C-Note | REMORA | DocuMaker

Hospital

Consultation Service

- E-prescription
- Cyber security
- My Number health insurance card
- Digital/data collaboration with other companies

Public Document Management System

DocuMaker Office

- Expansion of the document management system in line with national policies
- Establishment and consolidation of the stock business

Utilization of EMR Data

- Next Generation Medical Infrastructure Act
- Anonymization and Pseudonymization of EMR Data
- Driving drug discovery, AI development, and epidemiology

Overseas

Cloud-based/ On-premises Medical Software


Medical Device

GAP-screener | GAP

- Establishing a new standard for visual field testing
- Enhance global sales of our own medical device
- Implementation of contrast sensitivity testing
- R&D and market launch as a diagnostic device for MCI

©2026 FINDEX Inc.

Medical Business - Our Flagship Solutions



©2026 FINDEX Inc.

Shareholders Information (as of June 30, 2026)


Appendix

Number of shares and shareholders

Total number of authorized shares	78,336,000
Total number of issued shares	26,608,800
Number of shareholders	4,905

Breakdown of shares by type of shareholder

Type	# of shares	# of shareholders	% of total shares in issue
Japanese financial institutions	6,589,700	13	24.8
Japanese securities companies	522,580	26	2.0
Other Japanese companies	424,317	34	1.6
Foreign investors	2,437,799	88	9.2
Japanese individuals, others (Including treasury shares)	16,634,404	4,744	62.5
Total	26,608,800	4,905	100.0



Principal shareholders


Name	# of shares	% of total shares in issue
Teruo Aibara	7,707,600	31.4
The Master Trust Bank of Japan, Ltd. (Trust Account)	2,281,100	9.3
Mizuho Trust & Banking Co., Ltd. Securities Custody Trust 0700068	1,440,000	5.9
Mizuho Trust & Banking Co., Ltd. Securities Custody Trust 0700067	1,440,000	5.9
THE BANK OF NEW YORK MELLON 140040 (Standing proxy: Settlement Sales Division, Mizuho Bank, Ltd.)	1,327,500	5.4
Ehime Bank, Ltd.	967,200	3.9
Keiji Takemura	801,000	3.3
SCBHK AC LIECHTENS TEINISCHE LANDESBANK AG (Standing proxy: Mitsubishi UFJ Bank, Ltd.)	275,000	1.1
IB Investment Limited Partnership / General Partner IB K.K.	272,100	1.1
Daiwa Securities Co.Ltd.	259,500	1.1

*English names for certain shareholders/entities are unofficial translations for reference purposes only.

©2026 FINDEX Inc.

Sales Growth by Product & Service Category

Appendix




©2026 FINDEX Inc.


Financial Indicators

Appendix


ROE and DuPon Analysis




ROIC and Equity Ratio



Cash Flow



Marginal profit Ratio



©2026 FINDEX Inc.



©2026 FINDEX Inc.